Stopped losing on the top GLP-1 dose: is this only for weight loss?

You reached the top of the titration schedule months ago. The scale moved steadily for a while, then slowed, then stopped, and it has sat within a few pounds of the same number ever since. Once a month a telehealth clinician spends about fifteen minutes on your file, confirms the refill, asks whether the side effects are tolerable, and signs off. When you asked what comes next, you were told you are already on the highest dose and there is nothing else to try.

If you have stopped losing on the top GLP-1 dose, the question you are likely to type before paying for anything new is a reasonable one: is a membership like GoodLife Health only for weight loss, the same prescription under a different name and at a higher price? The answer is no. That answer matters more for you than for almost anyone else, because you have already used up the one lever a weight-loss prescription has.

The patient in this piece is a composite, not a real person or a real record. Here is the direct answer to the question. The membership is cardiometabolic primary care. Four lab panels a year read insulin, blood sugar, lipids, inflammation, thyroid and hormones. A clinician who stays reads them with you. A GLP-1 is one possible part of the plan, not the whole of it.

Fifteen minutes a month, and no next rung

A dose schedule is built to go up. Each step on it answers one question, whether to stay or to escalate, and the monthly visit exists to answer it. That design works while there is a next step. At the top, the visit has nothing left to decide, so it shrinks to a confirmation: you are still on the medication, you still want it, here is the renewal. Fifteen minutes is enough time for that task. It is far too short for the task you now have, which is finding out why the curve flattened.

Look at what your file probably contains: a starting weight, a questionnaire, your answers about side effects, and a record of each refill. If labs were drawn, they may have been drawn once, at the start, and never repeated. The side effects you raised early on may have been met with advice to wait, and you may have stopped raising them. Nobody has asked what your fasting insulin was before you started or what it is now. Nobody has checked your thyroid, or what your lipids did while the scale moved and then stopped.

If your prescription comes from a compounding pharmacy, there is a second layer. You have read about the FDA's position on compounded copies and the manufacturers' lawsuits, and nobody on the platform has explained what any of it means for the vial in your refrigerator.

None of this is a failure on your part. You did what the program asked. You took the medication, climbed the doses, lost weight, and kept going when the losing stopped. "Nothing else to try" lands like a verdict on you. It describes the model you were in. A model whose only output is weight and whose only lever is dose has nothing more to offer once the dose reaches its ceiling. That tells you where the model ends. It tells you nothing yet about your body.

What a plateau at the top dose can and cannot tell you

A plateau tells you one fact: your weight has stopped falling at this dose. It cannot tell you why. It cannot tell you whether your blood sugar, insulin, lipids or inflammation markers are where they should be at this weight. It cannot tell you whether something outside the metabolic system, such as a thyroid or hormone problem, is part of the picture. Those are questions for a blood draw, and a refill does not ask them.

The trials help frame the problem, though they cannot answer it for you. In STEP 1, semaglutide 2.4 mg produced roughly 15% average body-weight loss over 68 weeks. In SURMOUNT-1, tirzepatide produced up to about 21% over 72 weeks. Those are averages. An average contains people who lost more and people who lost less. Where you sit in that range is a fact about your own biology, and your own biology is exactly what has not been measured.

The definitive guide to cardiometabolic optimization describes the system that sits underneath the scale. Insulin resistance drives weight gain, visceral fat disrupts hormones, disrupted hormones stall metabolism, and stalled metabolism feeds vascular inflammation. Each part pushes on the others. The same guide names the gap most relevant to you: hormonal health is the axis most weight-loss platforms skip entirely, and the reason so many protocols stall. A program that measures only weight cannot see any of that. It can only see that the line went flat.

The direction the field is moving is concrete. Cardiometabolic care is being rebuilt around testing before treating. ApoB is read beside the old LDL, and fasting insulin beside the old glucose. Lp(a) and hs-CRP are drawn rather than assumed. The same markers are repeated every quarter, so a treatment decision becomes a feedback loop instead of a guess. Membership care is replacing the short visit because that kind of reading needs time and continuity, and a monthly renewal is built to provide neither. Branded medication is now sold by the manufacturers themselves at published self-pay prices, which separates the question of what to take from the question of who profits from it.

We do not know what your numbers will show. They might point to something treatable that has been holding the plateau in place. They might show that your markers are where they should be and that this weight is where your body has settled on this medication. They might show something that matters more than the scale. Each of those is an answer, and each is worth more than another month of a renewal that nobody reads.

What the membership does about it, what it costs, and what it does not do

GoodLife Health is clinician-led precision direct primary care for Cardiometabolic Optimization: diagnosis first, then treatment, then the long haul. Weight is one of the outcomes it follows, alongside the markers that explain it.

The membership includes four cardiometabolic lab panels a year, drawn quarterly, with every result in your hands. The guide lists what those panels read: ApoB, Lipoprotein(a), hs-CRP, HbA1c and insulin markers, lipids, and full hormone and thyroid panels. Clinicians are licensed in all fifty states. Yours reads the results with you by video and stays reachable through asynchronous messaging between visits. Because the clinician stays, the plateau is read over time instead of in one snapshot.

What the clinician does next depends on the panel, and the membership does not promise which way it goes. The GLP-1 might stay where it is. It might change to another branded medication: Wegovy, Zepbound, Mounjaro or Ozempic. The panel might point somewhere else, such as thyroid or hormones, where thyroid medication or hormone therapy can be prescribed when indicated. Any FDA-approved medication a clinician judges indicated can be prescribed to your pharmacy. The guide also describes the other direction: doses held at the lowest effective level, and deprescribing, when the labs support it, counted as a success. If hormone therapy becomes part of your plan, the medication is inexpensive at the pharmacy. The hormone pricing piece lists estradiol tablets at about $34 to $35 a month.

The fee is $299 a month whatever is prescribed and at whatever dose. There is no molecule upcharge and no dose upcharge, so nothing in your plan depends on selling you a stronger drug or a higher dose. That is the plain answer to "only for weight loss": the membership pays for the clinical work, and the clinical work covers the whole cardiometabolic system.

"Why pay a membership when the drug is the expensive part?" The drug is billed separately, by the pharmacy you choose, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. For reference, these are the manufacturers' own self-pay prices as published in September 2026. Through NovoCare, Wegovy pens were $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after, and the Wegovy pill started at $149 a month at lower doses. Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose. Whether your insurance covers a medication is between you, your plan and the pharmacy. Prior authorization is the pharmacy's process. We promise neither.

"I can get the prescription for $99 online." You can. The difference worth weighing is the incentive. When care is priced around the drug, the visit is organized around the drug, and when the drug reaches its top dose, the visit has nothing left to organize. That is where you are now. GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and it sells neither the drug nor the dose.

"I already have a prescriber." You do, and they have kept the refill going. The membership adds the primary-care relationship around it: the panel, the reading and the follow-up. It replaces that relationship. It does not replace your insurance, which you keep for the hospital and for catastrophic coverage.

If your top dose comes from a compounded vial, one line here is firm. GoodLife Health prescribes branded, FDA-approved medication only and never compounded GLP-1. The reasons are public. The FDA has set out its concerns about unapproved GLP-1 drugs used for weight loss, the manufacturers have gone to court over compounded copies, and dosing and additive practices in compounded products have been reported to vary. A clinician's licence carries the responsibility for what is prescribed, and that is where we draw the line. If a branded medication is indicated for you, the clinician prescribes it to your pharmacy at that pharmacy's price.

The membership does not promise a number on the scale, a remission or a cure. It does not promise that a medication will be covered. It does not accept everyone: the path is the eligibility check, the intake, the checkout, then a clinician's review, and the clinician may decide this is not the right care for you. The fee is generally eligible for HSA or FSA pre-tax dollars.

Before you decide: what to do this week

Whether or not you join, four things are worth doing in the next few days.

1. Ask your current prescriber for a copy of every lab result in your file since you started. If there are none, that tells you something too.
2. Write your history down in one place: the date you started, each dose step and when it happened, your weight at each step, every side effect, and the month the losing stopped. Any clinician can do more with that page than with your memory of it.
3. Ask your current clinician four direct questions. Has my fasting insulin been drawn, and what was it? What is my HbA1c? Has my thyroid been checked? Have my lipids and ApoB been measured? The answers will show whether anyone has looked under the plateau.
4. Keep taking the medication as prescribed while you find out. The plateau is a good reason to ask questions and a poor reason to make changes alone.

Who this is not for

If you want a dose above the top one, or someone who will keep the refill coming without drawing a single tube of blood, this is not for you. If you chose your current app for the $99 price and price is the one thing you would move for, the membership will feel expensive for what you want. If you want compounded GLP-1, research peptides, a guaranteed result, a promise that insurance will cover your medication, or a membership to replace your health insurance, we cannot offer any of it. If you live outside the fifty states, we cannot care for you. Turning those patients away is deliberate, because the model works only for someone who wants to be tested first.

The offer, in full: the membership is $299 a month. $598 is charged at sign-up and covers the first two months, and after that it is month to month. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable, and any medication billed by a pharmacy follows that pharmacy's own return and refund policy. It buys a cardiometabolic panel every quarter, a clinician who stays and reads them with you, and medication prescribed when indicated to the pharmacy you choose at that pharmacy's price, with nothing taken on it. It returns what fifteen-minute renewals have not produced: a diagnosis of what sits under your plateau, your markers followed over time, and an end to visits that close on "nothing else to try." It is different because it tests first, treats second, and sells neither the drug nor the dose. The reason to start now is your own situation. You are at the top of the dose, the ladder you are on has no next step, and every month without a panel is another month of the same refill.

Related Reading

• Cardiometabolic Optimization: The Definitive Guide
• Bioidentical Hormone Therapy at Pharmacy Cost: The Real Numbers

References

1. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
2. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/